JP2024510502A5 - - Google Patents

Info

Publication number
JP2024510502A5
JP2024510502A5 JP2023557351A JP2023557351A JP2024510502A5 JP 2024510502 A5 JP2024510502 A5 JP 2024510502A5 JP 2023557351 A JP2023557351 A JP 2023557351A JP 2023557351 A JP2023557351 A JP 2023557351A JP 2024510502 A5 JP2024510502 A5 JP 2024510502A5
Authority
JP
Japan
Prior art keywords
compound according
independently selected
sulfur
nitrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020474 external-priority patent/WO2022197755A1/en
Publication of JP2024510502A publication Critical patent/JP2024510502A/ja
Publication of JP2024510502A5 publication Critical patent/JP2024510502A5/ja
Pending legal-status Critical Current

Links

JP2023557351A 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤 Pending JP2024510502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162494P 2021-03-17 2021-03-17
US63/162,494 2021-03-17
PCT/US2022/020474 WO2022197755A1 (en) 2021-03-17 2022-03-16 Imidazopyridinyl inhibitors of plasma kallikrein

Publications (2)

Publication Number Publication Date
JP2024510502A JP2024510502A (ja) 2024-03-07
JP2024510502A5 true JP2024510502A5 (enExample) 2025-03-21

Family

ID=81325446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557351A Pending JP2024510502A (ja) 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤

Country Status (4)

Country Link
EP (1) EP4308227A1 (enExample)
JP (1) JP2024510502A (enExample)
CN (1) CN117396473A (enExample)
WO (1) WO2022197755A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
EP2627178B1 (en) * 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
US10065934B2 (en) * 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN117396474A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂
BR112023018619A2 (pt) * 2021-03-17 2023-11-28 Takeda Pharmaceuticals Co Inibidores de heteroaril de calicreína plasmática

Similar Documents

Publication Publication Date Title
JP2024510502A5 (enExample)
DE69108138T2 (de) Imidazopyridinderivate und ihre Verwendung.
KR101678255B1 (ko) 치환 아미드 화합물
JP2021527126A5 (enExample)
JP2024516073A5 (enExample)
JP5596680B2 (ja) 経口抗がん製剤
AU2017254523A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP5819954B2 (ja) 抗炎症剤、免疫調節剤及び抗増殖剤としての化合物の新規カルシウム塩
JP2024510503A5 (enExample)
JP2021120401A (ja) 水溶性プロドラッグ
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2009533398A (ja) アルテミシニン誘導体の二量体、この調製およびこの治療上の使用
CN120418236A (zh) 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
JP2024510504A5 (enExample)
JP2021512132A (ja) 置換イミダゾールカルボン酸エステル系誘導体およびその使用
BG65135B1 (bg) Производни на изосорбид мононитрат и тяхното използване като вазодилатиращо средство с намалена толерантност
JP2024512497A5 (enExample)
RU2007106037A (ru) Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов
JP2008519824A (ja) 腫瘍壊死因子アルファの阻害剤としての縮合三環系化合物
KR20060109871A (ko) 증식성 질병 치료용 알파, 베타-불포화 설폭시드
CN113024422B (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
LV10712B (en) 2-ciano-3-hydroxypropene amides
RU2004111789A (ru) Ретиноидные агонисты
WO2005061492A1 (ja) 含窒素複素環化合物およびそれらを有効成分とする薬剤
JPH0356488A (ja) 抗アテローム性動脈硬化症アザフロクロモン